Background
==========

The induction of potent mucosal immune responses will be critical for an effective HIV vaccine, However, a major limitation of current vaccine development is the ability to induce mucosal antibodies by a systemic, non-replicating vector. To address this inadequacy, we have hypothesized that encoding instructions for immune cell targeting to the mucosa in the form of MEC, a mucosal chemokine adjuvant delivered as a plasmid can redirect immune responses in vivo. MEC (CCL28) is normally expressed by epithelium in the skin, lungs, and intestines and it functions to attract CCR10 expressing plasmablasts locally.

Methods
=======

IIndian rhesus macaques were vaccinated using EP delivery with either a pcon SIVmac239 gag, pol, SIVsm unmatched E660 env vaccine delivered IM alone (n=5), with CCL28 (MEC, n=5) or a plasmid expressed H1 HA Influenza vaccine alone (n=4) or with MEC (n=4). SIV Vaccinated animals and 6 naïve controls were challenged vaginally twice weekly for four weeks with 500TCID50 SIVsmE660.

Results
=======

The inclusion of a CCR10 ligand adjuvant enhanced vaginal and serum IgG and IgA titers compared with DNA alone. In Flu vaccinated animals functional HAI antibody titers were significantly elevated and above the 1:40 titer required for protection in humans with just a single dose of H1HA delivered with the MEC adjuvant. Following SIV challenge monkeys vaccinated with a CCR10 adjuvant showed 89% protection from the establishment of infection compared 40% with DNA alone with only 16% of the naïve animals.

Conclusion
==========

Mucosal and systemic antibody responses were enhanced with the inclusion of a CCR10 ligand adjuvant. Dose sparing was also observed. DNA vaccination alone improved challenge outcome, and this was further enhanced by the inclusion of a CCR10 ligand adjuvant. The inclusion of mucosal homing chemokines represents a novel approach to induce improved mucosal immune responses by non-live systemic immunization of relevance to HIV infection.
